Ability to give written informed consent to the study
End-stage renal disease treated with thrice-weekly hemodialysis for at least 180 days preceding enrollment
Receiving intradialytic Crit-Line® monitoring, with available Crit-Line® data going back at least 180 days from the date of enrollment
Laboratory Hgb data going back at least 180 days from the date of enrollment
On average, Hgb values available from at least 2 treatments per week (from either source, Crit-Line® or laboratory) during the past 180 days preceding enrollment
Renal anemia treated with intravenous Mircera®, with at least 2 Mircera® dose administrations during the 150 days preceding enrollment
On an active Mircera® anemia management algorithm order during the 180 days preceding enrollment
Exclusively on Mircera® (no other ESAs) during the 180 days preceding enrollment
Pattern of Hgb cycling as defined above during the 180 days preceding enrollment
You may not be if
Having received the maximum Mircera® dose (225 µg every other week) consistently throughout the 90 days preceding enrollment
Hospitalization for more than 10 days during the 30 days preceding enrollment
Severe iron deficiency (TSAT \<20%, ferritin \<100 ng/mL) in the most recent routine blood work prior to enrollment
Any known cause of ESA resistance other than iron deficiency and inflammatory states (e.g. hematologic malignancies, hypersplenism, antibody mediated pure red cell aplasia)
Simultaneous participation in another clinical study that may impact anemia management or the outcomes of this trial
